Arginase inhibitors might prevent diabetic heart disease
Researchers may have discovered why diabetes leads to heart disease, despite intensive lifestyle interventions. Scientists from the Karolinska Institutet and Karolinska University Hospital have found a key enzyme known as arginase could be responsible for plaque formation and artery constriction that leads to angina for type 2 diabetics.
Arginase blocks nitric oxide (NO) that is naturally produced in the body and essential for keeping blood vessels relaxed. Diabetes complications occur when blood vessels become constricted from plaque formation or atherosclerosis.
Recently, researchers found even with interventions like weight loss, medications and exercise, heart disease risk remained high for people living with the disease.
The trial, called the Look AHEAD study was stopped because researchers failed to find ways to prevent cardiovascular problems in diabetics through intensive lifestyle interventions, making arginase an important new focus.
Heart disease is a leading source of death and disability associated with diabetes. According to the National Diabetes Information Clearinghouse (NIDC), adults with diabetes are 2 to 4 times more likely to develop heart disease than non-diabetics.
A 2009 study from Georgia Health Scientists pinpointed elevated arginase levels as a cause of diabetic eye disease or retinopathy that can lead to blindness.
Dr. Wenbo Zhang, the paper's first author said in a press release regarding the study, “…understanding just how arginase regulates inflammation should lead to new therapies for many acute and chronic inflammatory diseases in the eyes and other organs.” The finding was published in the American Journal of Pathology.
Similarly, Penn State scientists discovered arginase also plays a role in diabetic kidney disease, in findings published last year.